^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    RAD52 (RAD52 Homolog DNA Repair Protein)

    i
    Other names: RAD52, RAD52 Homolog DNA Repair Protein, DNA Repair Protein RAD52 Homolog, Rhabdomyosarcoma Antigen MU-RMS-40.23, RAD52 (S. Cerevisiae) Homolog, RAD52 Homolog (S. Cerevisiae), Recombination Protein RAD52
    17d
    Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) (clinicaltrials.gov)
    P2, N=120, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Dec 2029 | Trial primary completion date: Feb 2026 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • HRD (Homologous Recombination Deficiency) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • FANCL (FA Complementation Group L) • RAD52 (RAD52 Homolog DNA Repair Protein)
    |
    PD-L1 expression
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    26d
    The human RAD52 complex undergoes phase separation and facilitates bundling and end-to-end tethering of RAD51 presynaptic filaments. (PubMed, Nucleic Acids Res)
    Additionally, we show that RAD52 induces end-to-end tethering of RAD51 nucleoprotein filaments. Collectively, these findings highlight distinctive macromolecular organizational features of RAD52 that may underpin its diverse cellular functions.
    Journal
    |
    BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • RAD51 (RAD51 Homolog A) • RAD52 (RAD52 Homolog DNA Repair Protein)
    1m
    Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco) (clinicaltrials.gov)
    P2, N=334, Not yet recruiting, Fudan University
    New P2 trial • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • RAD51 (RAD51 Homolog A) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD50 (RAD50 Double Strand Break Repair Protein) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • FANCM (FA Complementation Group M) • RAD52 (RAD52 Homolog DNA Repair Protein) • RPA1 (Replication Protein A1) • PARP2 (Poly(ADP-Ribose) Polymerase 2)
    |
    HER-2 negative • PALB2 mutation • PGR positive • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation
    |
    capecitabine • AiRuiYi (fluzoparib)
    2ms
    Evidence of centromeric histone 3 chaperone involved in DNA damage repair pathway in budding yeast. (PubMed, Elife)
    Overall, from this report and earlier studies on HJURP, we conclude that DDR functions of CENP-A chaperones are conserved across eukaryotes. The revelation that these chaperones promote genome stability in more than one pathway has clinical significance.
    Journal
    |
    RAD52 (RAD52 Homolog DNA Repair Protein) • CENPA (Centromere protein A)
    3ms
    Germline lung cancer SNPs dysregulate known (LATS1) and novel (ADCY2) oncogenes through distal, spatially-constrained eQTLs. (PubMed, Cancer Genet)
    By linking germline variants to more biologically relevant gene targets and somatic processes, our results align more closely with established epidemiological and environmental risk factors for lung cancer, including a potential genetic explanation for the environmental interaction of caffeine and smoking in LC risk. This highlights the value of integrating 3D genome architecture and tissue-specific expression to refine our understanding of cancer susceptibility.
    Journal
    |
    RAD52 (RAD52 Homolog DNA Repair Protein) • CYP2A6 (Cytochrome P450 Family 2 Subfamily A Member 6) • LATS1 (Large Tumor Suppressor Kinase 1) • RIF1 (Replication Timing Regulatory Factor 1) • TP53BP1 (Tumor Protein P53 Binding Protein 1)
    3ms
    Mutations altering the DNA binding domains of the human RAD52 protein exert distinct effects on homologous recombination repair in Saccharomyces cerevisiae. (PubMed, G3 (Bethesda))
    We report that disrupting the internal and external DNA binding domains of HsRAD52 produced distinct effects on the repair of genomic DNA double-strand breaks (DSB) by conservative and non-conservative HRR in budding yeast, suggesting that these domains contribute to separate mechanisms in vivo. The further elucidation of the effects of perturbations in the structure and biochemical function of HsRAD52 in living systems will provide new insight into its ability to support DSB repair, cancer susceptibility as well as new avenues for targeting HRR-deficient cancers.
    Journal
    |
    HRD (Homologous Recombination Deficiency) • RAD52 (RAD52 Homolog DNA Repair Protein)
    4ms
    KAT2A-driven succinylation of SRSF11 enforces spliceosome-mediated RAD52 splicing to promote homologous recombination and radioresistance in hepatocellular carcinoma. (PubMed, Signal Transduct Target Ther)
    Notably, genetic disruption of the KAT2A-SRSF11 axis sensitizes HCC cells to radiation-induced apoptosis. Our findings establish succinylation as a novel regulatory mechanism linking alternative splicing to DNA repair fidelity in HCC, while proposing therapeutic targeting of this pathway to overcome radioresistance in advanced HCC.
    Journal
    |
    RAD51 (RAD51 Homolog A) • RAD52 (RAD52 Homolog DNA Repair Protein)
    5ms
    Targeting RAD52 overcomes PARP inhibitor resistance in preclinical Brca2 -deficient ovarian cancer model. (PubMed, bioRxiv)
    Finally, the RAD52 inhibitor D-I03 synergized with a PARP inhibitor to reduce cell viability and tumor burden and prolong survival. Collectively, our findings establish RAD52 as a promising therapeutic target to overcome PARP inhibitor resistance in BRCA2 -mutated ovarian cancer and offer mechanistic insights to inform future clinical strategies.
    Preclinical • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • RAD52 (RAD52 Homolog DNA Repair Protein)
    |
    BRCA mutation
    5ms
    Break-induced replication is activated to repair R-loop-associated double-strand breaks in SETX-deficient cells. (PubMed, Cell Rep)
    Hyper-resection further enhances PCNA ubiquitination and PIF1 loading, driving BIR-mediated hyper-recombination. Moreover, dysfunctional SETX is synthetic lethal with loss of PIF1, RAD52, or XPF, offering new strategies for targeted treatment of SETX-deficient tumors.
    Journal
    |
    PCNA (Proliferating cell nuclear antigen) • RAD52 (RAD52 Homolog DNA Repair Protein)
    6ms
    Regulation of Tetraspanin CD63 in Chronic Myeloid Leukemia (CML): Single-Cell Analysis of Asymmetric Hematopoietic Stem Cell Division Genes. (PubMed, Bioengineering (Basel))
    The single-cell trajectory reconstitution analysis in CP samples showed CD63 regulation highlighting a trajectory cluster implicating HSPB1, PIM2, ANXA5, LAMTOR1, CFL1, CD52, RAD52, MEIS1, and PDIA3, known to be implicated in hematopoietic malignancies. (4) Regulation of CD63, a tetraspanin involved in the asymmetric division of hematopoietic stem cells, was found to be associated with poor prognosis during CML progression and could be a potential new therapeutic target.
    Journal
    |
    MEIS1 (Meis Homeobox 1) • CD52 (CD52 Molecule) • RAD52 (RAD52 Homolog DNA Repair Protein) • HSPB1 (Heat shock 27kDa protein 1) • PDIA3 (Protein Disulfide Isomerase Family A Member 3) • ANXA5 (Annexin A5) • LAMP2 (Lysosomal Associated Membrane Protein 2)
    7ms
    Predictive value of homologous recombination-related gene mutations in survival outcomes of first-line nivolumab plus chemotherapy for gastric cancer. (PubMed, Gastric Cancer)
    HRR mutations were associated with favorable survival outcomes in patients treated with nivolumab plus chemotherapy. Our findings suggest that HRR mutations may serve as a potential predictive biomarker for first-line ICI-based chemotherapy in gastric cancer.
    Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • PALB2 (Partner and localizer of BRCA2) • RAD51 (RAD51 Homolog A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • POLD1 (DNA Polymerase Delta 1) • RAD51C (RAD51 paralog C) • RAD50 (RAD50 Double Strand Break Repair Protein) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1) • MRE11A (MRE11 homolog, double strand break repair nuclease) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • XRCC2 (X-Ray Repair Cross Complementing 2) • RAD52 (RAD52 Homolog DNA Repair Protein)
    |
    PALB2 mutation • BRIP1 mutation • RAD51C mutation • POLD1 mutation • RAD51D mutation • BARD1 mutation
    |
    Opdivo (nivolumab)
    8ms
    RDM1 plays an oncogenic role in clear cell renal cell carcinoma potentially by modulating MCM2. (PubMed, Sci Rep)
    From the mechanism perspective, RDM1 drove MCM2 to modulate ccRCC cell cycle. Thus, RDM1 inhibition blocks cell cycle progression, suppresses ccRCC cell growth, and is a promising approach for treating ccRCC.
    Journal
    |
    RAD52 (RAD52 Homolog DNA Repair Protein) • MCM2 (Minichromosome maintenance complex component 2)